Adjupanrix (previously Pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) GlaxoSmithKline Biologicals) (pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted))
Exceptional circumstances
- Region
- 🇪🇺 EU
- Active substance
- pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted)
- Company
- GlaxoSmithKline Biologicals S.A.
- Status
- Authorised
- Therapeutic area
- Influenza, Human; Immunization; Disease Outbreaks
- EU approval
- Sat 10 Oct 2009
- Designations
- Exceptional circumstances
- Application
- EMEA/H/C/001206
- ATC
- J07BB02
- Official record
- www.ema.europa.eu
Indication
Prophylaxis of influenza in an officially declared pandemic situation. Pandemic influenza vaccine should be used in accordance with official guidance.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Prepandrix Withdrawn · GlaxoSmithKline Biologicals S.A.
- 🇪🇺 Pumarix Withdrawn · GlaxoSmithKline Biologicals S.A.
- 🇪🇺 Prepandemic Influenza Vaccine (H5N1) (Split Virion, Inactivated, Adjuvanted) GlaxoSmithKline Biologicals Withdrawn · GlaxoSmithKline Biologicals S.A.
Follow Adjupanrix (previously Pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) GlaxoSmithKline Biologicals)
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.